RxDoctor Payments DataLook up a doctor →

Dana Morrel, MD

Internal Medicine · Tulsa, OKNPI 1417918954

Payments from drug & device makers

$13,705in general payments, 2019–2025

Across 828 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Pfizer$957
  • Lilly USA, LLC$917
  • Amgen$869
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$13,57999%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,705 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$178,543
Medicare patients
393
Services billed
2,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban171$149,592
MounjaroTirzepatide132$143,010
JardianceEmpagliflozin85$85,852
OzempicSemaglutide64$68,215
FarxigaDapagliflozin Propanediol54$52,342
MyrbetriqMirabegron61$37,531
JanuviaSitagliptin Phosphate23$26,140
RybelsusSemaglutide20$26,086
TrintellixVortioxetine Hydrobromide27$24,480
VascepaIcosapent Ethyl36$23,529
Repatha SureclickEvolocumab35$20,462
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,499
TrulicityDulaglutide19$18,026
KerendiaFinerenone15$16,547
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$11,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$917$161,036151 claims
PfizerEliquis$957$149,592171 claims
Novo NordiskOzempic, Rybelsus$1,545$94,30184 claims
Boehringer IngelheimJardiance$455$85,85285 claims
AstraZenecaFarxiga$1,303$52,34254 claims
MerckJanuvia, Belsomra, Janumet Xr$319$46,50055 claims
Astellas Pharma US IncMyrbetriq$296$37,53161 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$517$24,48027 claims
GSKTrelegy Ellipta$168$19,49929 claims
AbbVieSynthroid, Linzess$1,681$16,85695 claims
BayerKerendia$702$16,54715 claims
Johnson & JohnsonXarelto$183$11,14514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →